Hospitals, nursing homes can learn much from hospice care
Hospitals, nursing homes can learn much from hospice care

Publish on 1/23/2014 02:01:01 PM

Basic hospice strategies can make last days of dying inpatients more comfortable and dignified
The U.S. FDA vs. 23andMe
The U.S. FDA vs. 23andMe

Publish on 12/19/2013 11:12:18 AM

Some experts tell Knowledge@Wharton that? the real issue at stake in the controversy involving personal genomics and biotech company, 23andMe, is not innovation, but rather the firm’s selling strategy
Traffic-light coding system for emergency surgery
Traffic-light coding system for emergency surgery

Publish on 12/17/2013 03:12:20 PM

New classification system to improve scheduling of emergency surgery highlighted in special issue of 'British Journal of Surgery'
Counting the cost of infertility treatment
Counting the cost of infertility treatment

Publish on 12/9/2013 03:12:50 PM

From drug therapy to IVF, out-of pocket costs can range from $900 to $19,000 per treatment cycle, report researchers in 'The Journal of Urology'
Muscle loss and aging: Strategies, therapies to restore muscle health
Muscle loss and aging: Strategies, therapies to restore muscle health

Publish on 11/19/2013 06:11:11 PM

Mayo Clinic expert discusses notes that exercise remains the ‘silver bullet’ to maintain muscle mass in the aging
Biopharmaceuticals require more demanding packaging
Biopharmaceuticals require more demanding packaging

Publish on 10/28/2013 04:10:30 PM

New pharmaceuticals packages to be shown at interpack 2014 in Dusseldorf, protect proteins and prevent falsification
Single QMS audit program pilot for medical devices set for January 2014

Publish on 10/25/2013 01:10:13 PM

Medical device market regulators in Australia, Brazil, Canada and the US are preparing to launch a pilot for their Medical Device Single Audit Program (MDSAP) in January 2014. Read more
Chinese regulators considering new clinical trial, adverse event reporting requirements

Publish on 10/25/2013 01:10:49 PM

CHINESE medical device market regulators are three years away from full implementation of a new adverse event reporting and monitoring system, and may also establish a new clinical trial approval process for high-risk devices. Read more

Pages

 

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.